Omalizumab
"Omalizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA.
Descriptor ID |
D000069444
|
MeSH Number(s) |
D12.776.124.486.485.114.071.500 D12.776.124.486.485.114.224.060.844 D12.776.124.790.651.114.071.500 D12.776.124.790.651.114.224.060.844 D12.776.377.715.548.114.071.500 D12.776.377.715.548.114.224.200.844
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Omalizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Anti-Idiotypic [D12.776.124.486.485.114.071]
- Omalizumab [D12.776.124.486.485.114.071.500]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Omalizumab [D12.776.124.486.485.114.224.060.844]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Anti-Idiotypic [D12.776.124.790.651.114.071]
- Omalizumab [D12.776.124.790.651.114.071.500]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Omalizumab [D12.776.124.790.651.114.224.060.844]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Anti-Idiotypic [D12.776.377.715.548.114.071]
- Omalizumab [D12.776.377.715.548.114.071.500]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Omalizumab [D12.776.377.715.548.114.224.200.844]
Below are MeSH descriptors whose meaning is more specific than "Omalizumab".
This graph shows the total number of publications written about "Omalizumab" by people in this website by year, and whether "Omalizumab" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2006 | 0 | 2 | 2 | 2007 | 0 | 1 | 1 | 2009 | 0 | 1 | 1 | 2011 | 0 | 1 | 1 | 2013 | 0 | 1 | 1 | 2014 | 0 | 3 | 3 | 2015 | 1 | 1 | 2 | 2016 | 2 | 2 | 4 | 2017 | 4 | 0 | 4 | 2018 | 1 | 0 | 1 | 2020 | 1 | 5 | 6 | 2021 | 0 | 2 | 2 | 2022 | 1 | 0 | 1 | 2023 | 0 | 2 | 2 | 2024 | 5 | 2 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Omalizumab" by people in Profiles.
-
Brough HA, Kim EH, Anagnostou A, Lanser BJ, Chinthrajah RS, Sindher SB. Treatment of Food Allergy: Immunotherapy, Omalizumab, or Both. J Allergy Clin Immunol Pract. 2025 Apr; 13(4):731-739.
-
Anagnostou A, Bird JA, Chinthrajah S, Dribin TE, Fleischer DM, Kim E, Nowak-Wegrzyn A, Rachid R, Shaker MS, Shreffler W, Sicherer S, Tam J, Vickery BP, Virkud YV, Wang J, Young M, Greenhawt M. The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2025 Jan; 155(1):62-69.e1.
-
Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit? Ann Allergy Asthma Immunol. 2025 Jan; 134(1):110-121.
-
Boyd JT, Khanwalkar AR. Biologics in Chronic Rhinosinusitis: Current and Emerging. Immunol Allergy Clin North Am. 2024 11; 44(4):657-671.
-
Shaker M, Anagnostou A, Abrams EM, Lee M, Conway AE, Hsu Blatman KS, Oppenheimer J, Greenhawt M. The Cost-Effectiveness of Omalizumab for Treatment of Food Allergy. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2481-2489.e1.
-
Keller L, Stitt J. Chronic Spontaneous Urticaria: Quality of Life and Economic Impacts. Immunol Allergy Clin North Am. 2024 08; 44(3):453-467.
-
Casale TB, Fiocchi A, Greenhawt M. A practical guide for implementing omalizumab therapy for food allergy. J Allergy Clin Immunol. 2024 Jun; 153(6):1510-1517.
-
Sampson HA, Bird JA, Fleischer D, Shreffler WG, Spergel JM. Who are the potential patients for omalizumab for food allergy? Ann Allergy Asthma Immunol. 2024 05; 132(5):569-571.
-
Keller L, Perera EK, Bindon B, Khatiwada A, Stitt JM, Dreskin SC. Total IgE as a biomarker of omalizumab response in chronic spontaneous urticaria: A meta-analysis. Allergy Asthma Proc. 2024 Mar 01; 45(2):97-99.
-
Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, Yovetich N, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J, Wheatley LM, Chinthrajah RS. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024 03 07; 390(10):889-899.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|